È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·áº°, ¾àÁ¦º°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1701345
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 195 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 15¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2030³âÀÇ CAGRÀº -0.48%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ °¨¼Ò´Â ±âÁ¸ÀÇ È­Çпä¹ý¿¡ ºñÇØ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõÀÇ ¹ß»ý·üÀ» ÀúÇϽÃŰ´Â Ç¥Àû¾Ï Ä¡·á³ª ¸é¿ª¿ä¹ýÀÇ Ã¤¿ë È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇÑ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤¹ÐÀÇ·á°¡ Áøº¸ÇÔ¿¡ µû¶ó, Á¾¾çÀÇ»ç´Â °ñ¼ö ¾ïÁ¦ È¿°ú¸¦ ÃÖ¼ÒÈ­ÇÏ´Â Ä¡·á¹ýÀ¸·Î Á¡Á¡ ¿Å°Ü°¡°í ÀÖ¾î È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª °¡Á¤¿ë ÀÇ·á ¹× ÀÚ°¡Åõ¿©°¡´ÉÇÑ Ä¡·á¹ýÀÇ ´ëµÎ´Â Á¦¾à±â¾÷¿¡ À־ ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â »ç¿ëÇϱ⠽¬¿î Á¦Á¦¸¦ °³¹ßÇÒ ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù.

¾Ï Ä¡·á¿¡ ÀÇÇÑ ½É°¢ÇÑ ºÎÀÛ¿ëÀÎ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõÀº È­Çпä¹ýÀ» ¹Þ´Â ȯÀÚ¿¡°Ô Áß´ëÇÑ À§ÇèÀ» ÃÊ·¡ÇÕ´Ï´Ù. ¾Ï ȯÀÚÀÇ À¯º´·üÀÌ »ó½ÂÀ» °è¼ÓÇÏ´Â °¡¿îµ¥, È¿°úÀûÀÎ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ÀÇ·á ºÎ¹®ÀÇ ´ëÆøÀûÀÎ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. °³¹ß ±â¾÷Àº Ä¡·á Áøº¸, ½Å¾à °³¹ß ¹× ȯÀÚ °ü¸® ¼Ö·ç¼Ç °³¼±À» Ȱ¿ëÇÏ¿© ÀÌ·¯ÇÑ ½É°¢ÇÑ Áõ»óÀ» ÇØ°áÇÕ´Ï´Ù. ½ÃÀåÀº ¼ºÀå ÀÎÀÚ, Ç×»ýÁ¦, Ç×Áø±ÕÁ¦ ¹× ±âŸ Áö¿ø ¿ä¹ý¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¸¦ ¸ñ°ÝÇϰí ÀÖÀ¸¸ç È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) °ü¸® ¹× °ü·Ã ÇÕº´ÁõÀÇ °¨¼Ò¸¦ º¸ÀåÇÕ´Ï´Ù.

CIN°ú È¿°úÀûÀ¸·Î ½Î¿ì±â À§ÇØ ¼ºÀå ÀÎÀÚ´Â ¹éÇ÷±¸ »ý»êÀ» ÀÚ±ØÇϰí ÀÌȯÀÚÀÇ °¨¿° À§ÇèÀ» ¿ÏÈ­ÇÏ´Â Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÕ´Ï´Ù. Coherus BioSciences, Viatris Inc., Biocon Biologics Inc.¿Í °°Àº ÁÖ¿ä Á¦¾à ȸ»ç°¡ G-CSF °³¹ßÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù.

ÇÊ±Û¶ó½ºÆÀÀº È£Áß±¸ÀÇ È¸º¹À» ÃËÁøÇÏ´Â À¯ÀüÀÚ ÀçÁ¶ÇÕÇü G-CSF·Î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °£ÀÛ¿ë G-CSF·Î CIN¿¡ ´ëÇÑ È¿°úÀûÀÎ ¿¹¹æÀ» Á¦°øÇϸç, ¿¡ºêº£¸¶·¹³ë±Û¶ó½ºÆÀ ¾ËÆÄ´Â È£Áß±¸ ÁöÁö¸¦ °­È­Çϱâ À§ÇØ °³¹ß ÁßÀÎ Â÷¼¼´ë Ä¡·áÀÔ´Ï´Ù. Spectrum Pharmaceuticals, Inc., Evive Biotech, G1 Therapeutics, Inc.¿Í °°Àº ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷Àº ÀÌ·¯ÇÑ Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۱â À§ÇØ ¿¬±¸ °³¹ß¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ¼ºÀå ÀÎÀÚ¸¦ »ç¿ëÇØµµ CIN ȯÀÚ´Â ¼¼±ÕÀ̳ª Áø±Õ¿¡ °¨¿°µÇ±â ½±±â ¶§¹®¿¡ ¿¹¹æÀû¡¤Ä¡·áÀû Ç×»ýÁ¦ÀÇ »ç¿ëÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ºñ±³Àû Ä¡·áÀû Ç×»ýÁ¦´Â Àü¿°º´ÀÌ ¹ßº´ÇÑ °æ¿ì¿¡ Åõ¿©µË´Ï´Ù. ¿¹¹æÀû Ç×»ýÁ¦´Â È£Áß±¸ °¨¼ÒÁõ ȯÀÚÀÇ °¨¿°·üÀ» ÀúÇϽÃŰ´Â ¿¹¹æ Á¶Ä¡·Î¼­ ±â´ÉÇÏ´Â ¹Ý¸é, Ä¡·áÀû Ç×»ýÁ¦´Â ¸é¿ª°èÀÇ ÀúÇÏ·Î ÀÎÇÑ ¹ÚÅ׸®¾Æ °¨¿°¿¡ ´ëóÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ·¯ÇÑ ±âÁ¸ÀÇ Ä¡·á ¿É¼Ç ¿Ü¿¡µµ °ú¸³±¸ ¼öÇ÷°ú ¸é¿ªÁ¶ÀýÁ¦ µîÀÇ »õ·Î¿î Ä¡·á¹ýÀÌ È£Áß±¸°¨¼ÒÁõÀÇ ÁßÁõ·Ê¿¡ ´ëÇÑ ÀáÀçÀûÀÎ ÇØ°áÃ¥À¸·Î ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. È®¸³µÈ È¿´ÉÀÌ °è¼Ó ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖÁö¸¸, ¹ÙÀÌ¿À½Ã¹Ð·¯ ¾àÁ¦´Â ±× ºñ¿ë ´ë È¿°ú¿Í ä¿ë Áõ°¡¿¡ ÀÇÇØ ±Þ¼ÓÈ÷ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ¼±ÅÃÀÌ ³Î¸® ÀÌ¿ëµÉ ¼ö ÀÖ°Ô µÇ¾î, º¸´Ù ¸¹Àº ȯÀÚµéÀÌ °í°¡ÀÇ ¼±¹ß ¾àÁ¦ÀÇ °æÁ¦Àû ºÎ´ãÀ» ÁöÁö ¾Ê°í ÷´Ü Ä¡·áÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½Å¾àÀÇ °³¹ß°ú ÇÔ²² ¾à¹°Àü´ÞÀÇ Ä¡·á¹ýµµ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ºñ°æ±¸ Åõ¿©´Â ¿©ÀüÈ÷ CIN °ü¸®¿¡¼­ °ñµå Ç¥ÁØÀ̸ç, G-CSF ¹× Ç×»ýÁ¦ÀÇ °æ¿ì ½Å¼ÓÇϰí È¿°úÀûÀÎ °á°ú¸¦ ¾ò±â À§ÇØ Á¤¸Æ³» ¶Ç´Â ÇÇÇÏ Åõ¿©°¡ ±ÇÀåµË´Ï´Ù. ±×·¯³ª ¿¹¹æÀû Ç×»ýÁ¦¿Í ¸é¿ªÁ¶ÀýÁ¦ÀÇ °æ±¸ Åõ¿©´Â ¿Ü·¡ Ä¡·áÀÇ Æí¸®¼ºÀ» ³ôÀ̰í Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Åõ¿© ¹æ¹ýÀÇ º¯È­´Â ȯÀÚ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ°í ¸¸¼º Ä¡·á °ü¸®¿¡¼­ º´¿ø¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ °¨¼Ò½ÃŰ´Â Àü¹ÝÀûÀÎ ÀÇ·á µ¿Çâ°ú ÀÏÄ¡ÇÕ´Ï´Ù.

¾Ï ºÎ´ãÀÌ ¼¼°èÀûÀ¸·Î °è¼Ó Áõ°¡ÇÏ´Â °¡¿îµ¥ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº Å©°Ô È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ä¿ë Áõ°¡, ¾à¹° °³¹ßÀÇ Áö¼ÓÀûÀÎ ¹ßÀü, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ÀüüÀûÀ¸·Î CIN °ü¸®ÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÎÁöµµ Çâ»ó, Ä¡·á ÇÁ·ÎÅäÄÝ °³¼±, Áö¿ø ¿ä¹ý¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·áÀÇ ¹Ì·¡´Â Å« ÁøÀüÀ» È®ÀÎÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¼¼°è ÀÇ·á ¼Ö·ç¼ÇÀÇ Àü¹ÝÀûÀÎ ¹ßÀü¿¡µµ ±â¿©ÇÕ´Ï´Ù.

È­ÇÐ ¿ä¹ý À¯¹ß È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : Ä¡·á ºñÁî´Ï½º ºÐ¼®

Á¦5Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : ¾àÁ¦ ºñÁî´Ï½º ºÐ¼®

Á¦6Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : Åõ¿© °æ·Î ºñÁî´Ï½º ºÐ¼®

Á¦7Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : À¯Åë ä³Î »ç¾÷ ºÐ¼®

Á¦8Àå È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °æÀï ±¸µµ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Chemotherapy-induced Neutropenia Treatment Market Growth & Trends:

The global chemotherapy-induced neutropenia treatment market is anticipated to reach USD 1.51 billion by 2030 and is expected to decline at a CAGR of -0.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. This decline can be attributed to multiple factors, including the growing adoption of targeted cancer therapies and immunotherapies, which reduce the incidence of chemotherapy-induced neutropenia (CIN) compared to traditional chemotherapy. As precision medicine advances, oncologists are increasingly shifting towards treatment modalities that minimize myelosuppressive effects, thereby reducing the demand for CIN treatments. However, the rise of home healthcare and self-administrable therapies also presents an opportunity for pharmaceutical companies to develop user-friendly formulations that improve patient convenience.

Chemotherapy-Induced Neutropenia (CIN), a severe side effect of cancer treatment, poses significant risks for patients undergoing chemotherapy. As the prevalence of cancer cases continues to rise, the demand for effective CIN treatments is driving substantial growth in the healthcare sector. Businesses are capitalizing on advancements in treatment modalities, novel drug developments, and improved patient care solutions to address this critical condition. The market is witnessing increased investments in growth factors, antibiotics, antifungal agents, and other supportive therapies, ensuring better management of CIN and reducing associated complications.

To combat CIN effectively, growth factors play a vital role in stimulating white blood cell production, reducing the risk of infections in affected patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are the primary treatment option, enhancing neutrophil recovery and minimizing chemotherapy delays. Leading pharmaceutical companies such as Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Viatris Inc., and Biocon Biologics Inc. are at the forefront of G-CSF development.

Filgrastim is a widely used recombinant G-CSF that accelerates neutrophil recovery. Pegfilgrastim, a longer-acting version of Filgrastim, reduces the frequency of administration, while Lipegfilgrastim offers sustained neutrophil stimulation. Eflapegrastim is a novel, long-acting G-CSF providing effective prophylaxis against CIN, and Efbemalenograstim alfa is a next-generation therapy under development for enhanced neutrophil support. Additionally, Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs) are expanding the therapeutic potential in neutrophil recovery. Key market players, including Pfizer Inc., Spectrum Pharmaceuticals, Inc., Evive Biotech, and G1 Therapeutics, Inc., are actively investing in research and development to improve the efficacy of these treatments.

However, even with the use of growth factors, CIN patients remain highly susceptible to bacterial and fungal infections, making the use of prophylactic and therapeutic antibiotics crucial. Prophylactic antibiotics play a key role in preventing infections in high-risk patients, while therapeutic antibiotics are administered when infections develop. Similarly, antifungal agents help combat opportunistic infections, ensuring comprehensive patient care. These treatments collectively form a multi-layered defense system against the risks posed by CIN. Prophylactic antibiotics serve as a preventive measure to reduce infection rates in neutropenic patients, whereas therapeutic antibiotics help manage bacterial infections that arise due to the weakened immune system. Meanwhile, antifungal agents provide an added layer of protection against invasive fungal infections, which can be life-threatening for patients undergoing chemotherapy.

In addition to these conventional treatment options, emerging therapies such as granulocyte transfusions and immunomodulatory agents are gaining attention as potential solutions for severe cases of neutropenia. Ongoing research and innovation are expected to enhance the effectiveness and accessibility of these treatment options, further strengthening the market landscape. The CIN treatment market is divided into branded drugs and biosimilars. Branded drugs continue to dominate due to their established efficacy, but biosimilars are rapidly gaining traction due to their cost-effectiveness and increasing adoption. As regulatory approvals expand and healthcare accessibility improves, biosimilar options are becoming more widely available, allowing more patients to benefit from advanced therapies without the financial burden of high-priced branded drugs.

Along with the development of new drug options, treatment delivery methods are also evolving. Parenteral administration remains the gold standard for CIN management, with intravenous (IV) and subcutaneous (SC) routes being preferred for G-CSFs and antibiotics to ensure rapid and effective results. However, oral options for prophylactic antibiotics and immunomodulatory agents are gaining popularity, offering greater convenience for outpatient care. This shift in administration methods aligns with the broader healthcare trend of enhancing patient accessibility and reducing hospital dependency for chronic care management.

As the burden of cancer continues to grow worldwide, the CIN treatment market is poised for substantial expansion. The increasing adoption of biosimilars, continuous advancements in drug development, and ongoing research into innovative therapies are collectively shaping the future of CIN management. With enhanced awareness, improved treatment protocols, and growing investment in supportive care, the future of CIN treatment is set to witness significant progress. These developments not only ensure better patient outcomes but also contribute to the overall advancement of global healthcare solutions.

Chemotherapy-induced Neutropenia Treatment Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Variables, Trends, & Scope

Chapter 4. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Treatment Business Analysis

Chapter 5. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Drug Business Analysis

Chapter 6. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Route of Administration Business Analysis

Chapter 7. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Distribution Channel Business Analysis

Chapter 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â